Qingdao Haier Biomedical's (SHA:688139) unit, Qingdao Haier Blood Technology, plans to acquire an additional 2.53% stake in its subsidiary, Haier Blood Technology Chongqing, from two investors for 21.8 million yuan, according to the company's disclosure on the Shanghai Stock Exchange.
The stake will be bought from Qingdao Haiyu Chuangyuan Enterprise Management Partnership (Limited Partnership) and Qingdao Haiyu Yingkang Enterprise Management Partnership (Limited Partnership), the Saturday disclosure added.
Price (RMB): ¥35.23, Change: ¥-0.06, Percent Change: -0.17%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments